NCT07053683 is a NA clinical trial of Combined RME and Facemask Therapy in Skeletal Class III Malocclusion, sponsored by Wuhan Integrated Traditional Chinese and Western Medicine Hospital.

Who is sponsoring NCT07053683?

NCT07053683 is sponsored by Wuhan Integrated Traditional Chinese and Western Medicine Hospital.

What drugs are being tested in NCT07053683?

Interventions in NCT07053683: Combined RME and Facemask Therapy, Facemask Therapy Alone.

What condition does NCT07053683 study?

NCT07053683 studies Skeletal Class III Malocclusion.

Is NCT07053683 still recruiting?

NCT07053683 is currently completed. Last updated 22 August 2025.

Last reviewed 2025-08-22 · How we verify

NCT07053683

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of RME and Facemask Therapy for Class III Malocclusion

Completed NA Last updated 22 August 2025

What this trial tests

NA trial testing Combined RME and Facemask Therapy in Skeletal Class III Malocclusion in 358 participants. Completed in 31 December 2023.

Timeline

1 January 2019

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Wuhan Integrated Traditional Chinese and Western Medicine Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	358
Start date	1 January 2019
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across China

Drugs / interventions tested

Combined RME and Facemask Therapy
Facemask Therapy Alone

Conditions studied

Skeletal Class III Malocclusion — all drugs for Skeletal Class III Malocclusion →

Sponsor

Wuhan Integrated Traditional Chinese and Western Medicine Hospital

Who can join

Adults 7 to 12, any sex, with Skeletal Class III Malocclusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multicenter randomized controlled trial compares the efficacy of Rapid Maxillary Expansion (RME) combined with facemask (FM) protraction versus FM protraction alone in treating growing children with skeletal Class III malocclusion. The study aims to evaluate the differences in vertical skeletal changes and Oral Health-Related Quality of Life (OHRQoL) between the two treatments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Wuhan Integrated Traditional Chinese and Western Medicine Hospital trials

Trials by the same sponsor.

NCT07104526 — Low-Dose Propranolol and Bleomycin for Infantile Hemangioma (IH) · NA · completed
NCT07064980 — ERCP Versus PTBD for Severe Acute Cholangitis Caused by Bile Duct Stones · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07053683 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wuhan Integrated Traditional Chinese and Western Medicine Hospital
Last refreshed: 22 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07053683.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing